A Better Newspaper

## Overview China's pharmaceutical and biotech sector is experiencing a surge in high-value out-licensing deals, with AI increasingly positioned as an accelerant for drug discovery and development timelines (SCMP, April 2026). ## Deal Volume & Scale Recent transactions include (SCMP, April 2026): - **CSPC Pharmaceutical**: Out-licensing agreement worth up to **$18.5 billion** - **RemeGen**: Out-licensing agreement worth up to **$5.6 billion** - **Haisco Pharmaceutical Group**: Multiple deals, most recently worth up to **$745 million**, with the Beijing-based company granting rights to a US partner "A quarter featuring multiple eye-popping deals is no longer unusual for China's pharmaceutical industry – in fact, it may soon be considered a slow season" (SCMP, April 2026). ## AI's Role The article frames AI as a potential accelerator ('floor the accelerator') for Chinese biotech firms that are already achieving deal velocity through traditional drug development pipelines. AI applications include target identification, protein structure prediction, clinical trial design optimization, and regulatory submission preparation. ## Strategic Context - Chinese biotech firms are shifting from domestic-focused generics to global IP origination - Out-licensing to Western pharma validates Chinese R&D quality for international markets - AI-driven drug discovery (see also: Helical Ltd., OpenAI-Novo Nordisk partnership) is compressing development timelines globally - US export controls on AI chips could affect Chinese biotech AI infrastructure scaling ## Implications for Practitioners - IP licensing attorneys: Chinese out-licensing structures, milestone payment mechanisms, and territory carve-outs are increasingly complex - Life sciences investors: The deal pipeline suggests a structural shift in where global pharma innovation originates - Regulatory: FDA and EMA scrutiny of Chinese-origin biologics and small molecules will intensify as deal volume grows